C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

202211 citationsJournal Articlehybrid Open Access

Authors

NCT04351152; ClinicalTrials.gov.

Good health and well-being

Published in: Thorax

Volume 78, Issue 6, pp. thoraxjnl-2022

Field-Weighted Citation Impact: 1.11